- Email: [email protected]
Subject index volume 44
CONTRACEPTION
SUBJECT Volume
INDEX 44
June-December
1991
Abutilon
indicum, effect on uterine peroxidase activity (rat), 549 Acceptability study, use of female condom, 183 Acceptance, sterilization, 623 Advised birth control system, diaphragm tampon applied to ovulation method, 607 Antibodies generated by D-hCG vaccine, response to hCG stimulation test, 453 Antide, effect on hormonal levels (monkey), 667 effect on ovulation (monkey), 667 effect on pregnancy (rat), 209 LHRH antagonist, 209, 667 pharmacokinetics (monkey), 667 Antifertility activity, volatile fraction of neem oil (rat, rabbit, monkey), 319 Antifertility effects, immunization with human sperm antigen (rat), 559 At-risk populations, effect of ethinyl estradiol + norethindrone, 505 Billings Ovulation Method, with use of diaphragm tampon, 607 Binding affinities, various progestogens, 1 Bioavailability, norethindrone imonkey), 327 Biodegradable implant, Capronor , 409 Biological activity, effect of new progestogens, 1 Biological profile, CDRI-851287 (rat), 461 Bioself 110, electronic fertility indicator, 125 use as a contraceptive aid, 125 Bleeding pattern, use of depot-norethisterone enanthate, 639 use of estradiol valerate + norethisterone enanthate, 589 use of estradiol/progesterone formulation, 45 use of 3-keto-desogestrel, 393 use of levonorgestrel, 409 use of norgestrel, 31 Blood pressure, effect of levonorgestrel, 223 effect of norethisterone, 223 Bone metabolism, effect of GnRHAs, 289 Breastfeeding pattern, use of norgestrel, 31 Butea monosoerma, effect on uterine peroxidase activity (rat), 549 Cancer risk estimates, proposed GnRHA contraceptive regimen, 289 CapronorR, clinical trial of biodegradable implant, 409
DECEMBER 1991 VOL. 44 NO. 6
679
CONTRACEPTION
Carbohydrate effect effect effect effect effect CDRI-851287
metabolism, of depo-medroxyprogesterone acetate, 419 of levonorgestrel, 163, 232 of new progestogens, 1 of norethisterone, 223 of norethisterone enanthate, 419 (2-(4-(2-N-piperidinoethoxy)phenyl)-3-phenyl (2H) benzo (b) pyran, contraceptive activity (rat), 461 effect on pregnancy (rat), 461 effect on uterus (rat, rabbit), 461 Centchroman, effect on uterine peroxidase activity (rat), 549 Cervical cap, comparison to Fern Cap, 11 Cervical mucus, effect of intranasal norethisterone, 245 6-Chloro-6-deoxyglucose, antifertility activity, 649 effect on spermatozoa (rat, boar), 649 Clinical parameters, effect of ethinyl estradiol + norethindrone, 113 effect of ethinyl estradiol + norethindrone acetate, 113 effect of spironolactone, 113 Clinical trial, estradiol valerate + norethisterone enanthate, 589 Fern Cap, 11 3-keto-desogestrel implants, 393 levonorgestrel biodegradable implant, 409 Clomiphene citrate, effect on uterine peroxidase activity (rat), 549 Coagulation, effect of new progestogens, 1 Coagulation factors, effect of depo-medroxyprogesterone acetate, 431 effect of depot-norethisterone enanthate, 639 effect of levonorgestrel, 223 effect of norethisterone, 223 Coagulation function, effect of norethisterone enanthate, 73 Coagulation regulatory system, effect of IUDs, 367 Condom, female, acceptability study, 183 clinical study, 21 Contraceptive activity, CDRI-85/287 (rat), 461 Contraceptive aid, Bioself 110 electronic fertility indicator, 125 Contraceptive choice, following contraceptive failure, 83 Contraceptive failure, outcome of pregnancy and subsequent contraceptive choice, 83 Contraceptive practices, sexual habits and fertility patterns, community-based study, 445 Contraceptive regimen using GnRHA, 289 Copper release from IUDs, effect of tarnish, 385 Copper T 220, effect on endometrium, 367 Copper T 380A, clinical trial, 141 Copper T 380Ag, seven-year clinical study, 473
680
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Copper-releasing IUDs, review article, 573 Copper-T IUDs, clinical study, 481 review of literature, 341 Delaying menses, use of ethinylestradiol + desogestrel, 107 Depo-medroxyprogesterone acetate, effect on carbohydrate metabolism, 419 effect on coagulation factors, 431 effect on hormonal profile, 419 effect on lipid metabolism, 61, 431 serum level following administration, 61 Desogestrel, characteristics, 1 Diaphragm, clinical study, 21 Diaphragm tampon, Gynaeseal, 607 used with Billings Ovulation Method, 607 Discontinuation, use of biodegradable levonorgestrel implants, 409 Discontinuation rates and reasons, ethinyl estradiol + norethindrone, 489 mestranol + norethindrone, 489 Embelin (2,5-dihydroxy-3-undecyl-1,4_benzoquinone), effect on uterine peroxidase activity (rat), 549 mode of action (male rabbit), 311 Endometrial bleeding, effect of norethisterone enanthate, 73 Endometrial histology, effect of norethisterone enanthate, 73 Endometrial morphology, effect of intranasal norethisterone, 245 Endometrium, effect of IUDs, 367 Estradiol level, effect of estradiol/progesterone administration, 45 Estradiol valerate + norethisterone enanthate, clinical trial, 589 effect on lipid metabolism, 235 Estradiol/progesterone sustained release formulation, effect on ovulation, 45 Estrogenic/antiestrogenic potential of antifertility substances, effect on uterine peroxidase activity (rat), 549 Ethinylestradiol + desogestrel, ability to postpone withdrawal bleeding, 107 effect on hypothalamo-pituitary axis, 155 maintenance of remission of hirsutism, 533 Ethinyl estradiol + gestodene, effect on lipid metabolism, 235 Ethinyl estradiol + norethindrone, clinical study, 489 effect on lipid metabolism in at-risk populations, 505 rates and reasons for discontinuation, 489 treatment for hirsutism, 113 Ethinyl estradiol + norethindrone acetate, treatment for hirsutism, 113
DECEMBER 1991 VOL. 44 NO. 6
661
Failed contraception, outcome of pregnancy and subsequent contraceptive choice, 83 Family planning aid, Bioself 110 electronic fertility indicator, 125 Fern Cap, clinical trial, 11 intravaginal barrier contraceptive device, 11 Female condom, Femshie&j, 183 Female condom (Reality ), effect on lower genital tract, 21 effect on resident bacterial flora, 21 effect on vaginal mucosa and/or vulvar skin, 21 Female sterilization, acceptance and regret, 623 physicians' attitudes, recommendations and practice, Fernshield.wgl acceptability, 183 vaginal sheath, 183 Fertility indicator, Bioself 110 electronic device, 125 Fertility patterns, contraceptive practices and sexual habits, community-based study, 445 Folliculogenesis, effect of intranasal norethisterone, 245 FSH (follicle stimulating hormone) administration, FSH level, effect of estradiol/progesterone 45 Fucoidin, effect on spermatozoa, 657 effect on zona pellucida-sperm interaction, 657 Gestodene, characteristics, 1 GnRHA (gonadotrophin-releasing hormone agonist) GnRHA contraceptive regimen, cancer risk estimates, 289 Gonadotrophin-releasing hormone agonist (GnRHA), effect on bone metabolism, 289 effect on lipid metabolism, 289 effect on ovarian function, 289 use in proposed contraceptive regimen, 289 Gynaeseal, diaphragm tampon, 607 Gyne T 380, clinical study, 481 Gyne T 380 Slimline, clinical study, 481 hCG stimulation test, response of women immunized with B-hCG vaccine, 453 B-hCG vaccine, study on antibodies produced, 453 Hemostatic parameters, effect of nomegestrol acetate, 599 Hirsutism, maintenance of remission with ethinyl estradiol + desogestrel, 533 treatment with ethinyl estradiol + norethindrone, 113 treatment with ethinyl estradiol + norethindrone acetate, 113 treatment with spironolactone, 113 Hirsutism score, effect of ethinyl estradiol + desogestrel, 533
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Hormonal levels, effect of antide (monkey), 667 effect of depo-medroxyprogesterone acetate, 419 effect of ethinylestradiol + desogestrel, 155 effect of ethinyl estradiol + norethindrone, 113 effect of ethinyl estradiol + norethindrone acetate, 113 effect of intranasal norethisterone, 245 effect of 3-keto-desogestrel, 393 effect of nomegestrol acetate, 599 effect of norethisterone enanthate, 73, 419 effect of spironolactone, 113 effect of treatment with neem oil (monkey), 319 Hypospadias in infants, association to maternal oral contraceptive use, 173 Hypothalamo-pituitary axis, effect of ethinylestradiol + desogestrel, 155 Immunization with sperm antigen, effect on fertility (rat), 559 Implant contrficeptive, Capronor , 409 3-keto-desogestrel, 393 levonorgestrel, 163, 217, 409 norethindrone acetate (monkey), 327 Infant development, use of norgestrel in lactating women, 31 Infant hypospadias, association to maternal oral contraceptive use, 173 Injectable contraceptive, depo-medroxyprogesterone acetate, 61, 419, 431 estradiol valerate + norethisterone enanthate, 235, 589 estradiol/progesterone sustained release formulation, 45 norethisterone enanthate 73, 419, 639 Insertion procedure, Norplant k , 217 Intestinal complication, five years after Nova-T insertion, 517 Intranasal administration, norethisterone, 245 Intrauterine device (IUD), copper T 220, 367 Copper T 380A, 141, 385, 573 copper T 380Ag, 473, 573 copper-T devices, 341 effect of tarnish on copper release, 385 Gyne T 380, 481 Gyne T 380 Slimline, 481 levonorgestrel-releasing, 341, 367, 473, 573 Lippes C, 235 Lippes Loop D, 141 Multiload Cu 375, 141 multiload devices, 341 Nova-T, 235, 341, 517, 573 progesterone-releasing, 341 stainless steel ring, 367 TCu-200B, 573
DECEMBER 1991 VOL. 44 NO. 6
663
CONTRACEPTION
TCu-220C, 573 TCu-380, 541 Intravaginal barrier contraceptive device, Fern Cap, 11 IUD (intrauterine device) 3-Keto-desogestrel implants, clinical trial, 393 3-Keto-desogestrel level, during use of 3-keto-desogestrel implants, 393 Levonorgestrel, effect on carbohydrate metabolism, 163 metabolic effects, 223 Levonorgestrel biodegradable implant, clinical trial, 409 Levonorgestrel-releasing IUD, advantages of use, 573 disadvantages of use, 573 effect on endometrium, 367 performance, 573 review article, 573 review of literature, 341 seven-year clinical study, 473 traits comparable to copper-releasing IUDs, 573 LH (luteinizing hormone) LH level, effect of embelin (male rabbit), 311 effect of estradiol/progesterone administration, 45 LHFW (luteinizing hormone-releasing hormone) LHRH antagonist, antide, 209, 667 Lipid metabolism, effect of depo-medroxyprogesterone acetate, 431 effect of estradiol valerate + norethisterone enanthate, 235 effect of ethinyl estradiol + desogestrel, 533 effect of ethinyl estradiol + gestodene, 235 effect of ethinyl estradiol + norethindrone, 505 effect of GnFUiAs, 289 effect of 3-keto-desogestrel, 393 effect of levonorgestrel, 223 effect of Lippes C, 235 effect of new progestogens, 1 effect of norethisterone, 223 effect of Nova T, 235 Lipoprotein metabolism, effect of depo-medroxyprogesterone acetate, 61 Lippes C, effect on lipid metabolism, 235 Lippes Loop D, clinical trial, 141 Long-term intrauterine contraception, levonorgestrel and copper T 380Ag IUDs, 473 serious intestinal complication after Nova-T insertion, 517 Lower genital tract, effect of diaphragm, 21 effect of female condom, 21 Male antifertility activity, 6-chloro-6-deoxyglucose (rat, boar), 649
684
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Male sterilization, acceptance and regret, 623 physicians' attitudes, recommendations and practice, 191 Menstrual cycle, effect of intranasal norethisterone, 245 effect of norethindrone acetate (monkey), 327 Mestranol + norethindrone, clinical study, 489 rates and reasons for discontinuation, 489 Metabolic effects, use of ethinyl estradiol + norethindrone, 113 use of ethinyl estradiol + norethindrone acetate, 113 use of levonorgestrel, 223 use of nomegestrol acetate, 599 use of norethisterone, 223 use of spironolactone, 113 Metabolism, effect of new progestogens, 1 Metoclopramide-stimulated prolactin level, effect of TCu380, 541 Mifepristone (RU486), effect on prostaglandin synthesis and metabolism, 89 Multiload Cu 375, clinical trial, 141 Multiload IUDs, review of literature, 341 Natural hormones estradiol/progesterone in sustained release system, use as injectable contraceptive, 45 Neem oil, antifertility activity (rat, rabbit, monkey), 319 New progestogens, characteristics in combination oral contraceptives, 1 Nomegestrol acetate, effect on hormonal, metabolic and hemostatic parameters, 599 Norethindrone, bioavailability (monkey), 327 Norethindrone level, use of subdermal implants (monkey), 327 Norethisterone, effect on cervical mucus, 245 effect on endometrial morphology, 245 effect on folliculogenesis, 245 effect on hormonal levels, 245 effect on vaginal cytology, 245 metabolic effects, 223 Norethisterone enanthate, effect on blood coagulation factors and menstrual bleeding patterns, 639 effect on carbohydrate metabolism, 419 effect on coagulation function, 73 effect on endometrial bleeding, 73 effect on endometrial histology, 73 effect on hormonal profile, 419 effect on ovarian hormones, 73 Norgestimate, characteristics, 1 Norgestrel, clinical trial, 31 effect on breastfeeding, 31
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
NorplantR, comparison of insertion procedures, 217 effect on carbohydrate metabolism, 163 Nova-T, attributes, 341 effect on lipid metabolism, 235 epidemiologic considerations, 341 review of literature, 341 review of performance, 341, 573 serious intestinal complication five years after insertion, 517 service delivery considerations, 341 ON0 802, prostaglandin analogue, 523 Oral contraceptive, ethinylestradiol + desogestrel, 107, 155, 533 ethinylestradiol + gestodene, 235 ethinyl estradiol + norethindrone, 113, 489, 505 ethinyl estradiol + norethindrone acetate, 113 levonorgestrel, 223 mestranol + norethindrone, 489 nomegestrol acetate, 599 norethisterone, 223 norgestrel, 31 Oral contraceptive use, association to infant hypospadias, 173 Oral contraceptives, effect on vitamin status, 277 progestogen component of combination formulations, 1 Ovarian function, effect of GnRHAs, 289 Ovulation, effect of antide (monkey), 667 Ovulation method of birth control, efficacy and acceptability, 607 Performance, Nova-T, 341 PG (prostaglandin) PGF2, levels, in normal saline-induced abortions, 99 Physicians' attitudes, recommendation and practice of male and female sterilization, 191 Pituitary response, use of ethinylestradiol + desogestrel, 155 Postponement of withdrawal bleeding, use of ethinylestradiol + desogestrel, 107 Potency, various progestogens, 1 Pregnancy, effect of antide (rat), 209 effect of CDRI-85/287 (rat), 461 Pregnancy outcome, foliowing contraceptive failure, 83 Premenopausal women, effect of ethinyl estradiol + norethindrone, 505 Progesterone level, effect of antide (rat), 209 effect of embelin (male rabbit), 311 effect of estradiol/progesterone administration, 45 effect of ST-1435, 269 response in women immunized with 8-hCG vaccine, 453
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Progesterone-releasing IUD, review of literature, 341 Progestogens, in combination oral contraceptives, 1 Prolactin level, effect of TCu-380, 541 Prolonged intrauterine contraception, levonorgestrel and copper T 380Ag IUDs, 473 Prostaglandin analogue, ON0 802, 523 ndin synthesis and metabolism, effect of RU486, 89 ;:z;y;;#l effe& on lower genital tract, 21 female condom, 21 Regret, following sterilization, 623 Removals, use of 3-keto-desogestrel implants, 393 Review paper, Nova-T IUD, 341 RU486 (mifepristone) RU486 + ON0 802, acceptability as an abortion method, 523 side effects during treatment, 523 use for early termination of pregnancy, 523 Saline-induced abortions, PGF2, levels, 99 Sexual habits, contraceptive practices and fertility patterns, community-based study, 445 Side effects, use of biodegradable levonorgestrel implants, 409 use of estradiol valerate + norethisterone enanthate, 589 use of ethinyl estradiol + norethindrone, 489 use of GnRHAs, 289 use of IUDs, 141 use of mestrano + norethindrone, 489 use of Norplant h , 217 Smoking women, effect of ethinyl estradiol + norethindrone, 505 Sperm antigen, potential for use as contraceptive vaccine (rat), 559 Sperm antigen immunization, antifertility effects (rat), 559 Spermatozoa, effect of 6-chloro-6-deoxyglucose (rat, boar), 649 effect of fucoidin, 657 Spironolactone, treatment for hirsutism, 113 ST-1435 (16-methy1ene-17-acetoxy-19-nor-4-pregnene-3,20dione), transdermal absorption, 269 ST-1435 level, following transdermal application of ST-1435, 269 Stainless steel ring, effect on endometrium, 367 Sterilization, acceptance and regret, 623 factors affecting choice, 623 physicians' attitudes, recommendations and practice, 191 Steroidal effects, various progestogens, 1 Tarnish, effect on copper release from IUDs, 385 TCu IUDs, review of performance, 573 TCu-380, effect on prolactin levels, 541 Termination events, comparative clinical trials of IUDs, 141
DECEMBER 1991 VOL. 44 NO. 6
667
CONTRACEPTION
Termination of pregnancy, use of RU486 and ON0 802 in combination, 523 Testosterone level, effect of embelin (rabbit), 311 effect of ethinyl estradiol + desogestrel, 533 Transdermal absorption, ST-1435, 269 Triphasic ethinylestradiol + gestodene, effect on lipid metabolism, 235 Tubal ligation, physicians' attitudes, recommendations and practice, 191 Uterine peroxidase activity, effect of antifertility substances (rat), 549 Uterine weight, effect of antifertility substances (rat), 549 Uterus, effect of CDRI-851287 (rat, rabbit), 461 Vaccine contraceptive, B-hCG vaccine, 453 Vaginal bacterial flora, effect of diaphragm, 21 effect of female condom, 21 Vaginal cytology, effect of intranasal norethisterone, 245 Vasectomy, physicians' attitudes, recommendations and practice, 191 Vitamin status, effect of oral contraceptives, 277 Vitamin supplementation, effect in oral contraceptive users, 277 Zona pellucida-sperm interaction, effect of fucoidin, 657
DECEMBER 1991 VOL. 44 NO. 6
SUBJECT Volume
INDEX 44
June-December
1991
Abutilon
indicum, effect on uterine peroxidase activity (rat), 549 Acceptability study, use of female condom, 183 Acceptance, sterilization, 623 Advised birth control system, diaphragm tampon applied to ovulation method, 607 Antibodies generated by D-hCG vaccine, response to hCG stimulation test, 453 Antide, effect on hormonal levels (monkey), 667 effect on ovulation (monkey), 667 effect on pregnancy (rat), 209 LHRH antagonist, 209, 667 pharmacokinetics (monkey), 667 Antifertility activity, volatile fraction of neem oil (rat, rabbit, monkey), 319 Antifertility effects, immunization with human sperm antigen (rat), 559 At-risk populations, effect of ethinyl estradiol + norethindrone, 505 Billings Ovulation Method, with use of diaphragm tampon, 607 Binding affinities, various progestogens, 1 Bioavailability, norethindrone imonkey), 327 Biodegradable implant, Capronor , 409 Biological activity, effect of new progestogens, 1 Biological profile, CDRI-851287 (rat), 461 Bioself 110, electronic fertility indicator, 125 use as a contraceptive aid, 125 Bleeding pattern, use of depot-norethisterone enanthate, 639 use of estradiol valerate + norethisterone enanthate, 589 use of estradiol/progesterone formulation, 45 use of 3-keto-desogestrel, 393 use of levonorgestrel, 409 use of norgestrel, 31 Blood pressure, effect of levonorgestrel, 223 effect of norethisterone, 223 Bone metabolism, effect of GnRHAs, 289 Breastfeeding pattern, use of norgestrel, 31 Butea monosoerma, effect on uterine peroxidase activity (rat), 549 Cancer risk estimates, proposed GnRHA contraceptive regimen, 289 CapronorR, clinical trial of biodegradable implant, 409
DECEMBER 1991 VOL. 44 NO. 6
679
CONTRACEPTION
Carbohydrate effect effect effect effect effect CDRI-851287
metabolism, of depo-medroxyprogesterone acetate, 419 of levonorgestrel, 163, 232 of new progestogens, 1 of norethisterone, 223 of norethisterone enanthate, 419 (2-(4-(2-N-piperidinoethoxy)phenyl)-3-phenyl (2H) benzo (b) pyran, contraceptive activity (rat), 461 effect on pregnancy (rat), 461 effect on uterus (rat, rabbit), 461 Centchroman, effect on uterine peroxidase activity (rat), 549 Cervical cap, comparison to Fern Cap, 11 Cervical mucus, effect of intranasal norethisterone, 245 6-Chloro-6-deoxyglucose, antifertility activity, 649 effect on spermatozoa (rat, boar), 649 Clinical parameters, effect of ethinyl estradiol + norethindrone, 113 effect of ethinyl estradiol + norethindrone acetate, 113 effect of spironolactone, 113 Clinical trial, estradiol valerate + norethisterone enanthate, 589 Fern Cap, 11 3-keto-desogestrel implants, 393 levonorgestrel biodegradable implant, 409 Clomiphene citrate, effect on uterine peroxidase activity (rat), 549 Coagulation, effect of new progestogens, 1 Coagulation factors, effect of depo-medroxyprogesterone acetate, 431 effect of depot-norethisterone enanthate, 639 effect of levonorgestrel, 223 effect of norethisterone, 223 Coagulation function, effect of norethisterone enanthate, 73 Coagulation regulatory system, effect of IUDs, 367 Condom, female, acceptability study, 183 clinical study, 21 Contraceptive activity, CDRI-85/287 (rat), 461 Contraceptive aid, Bioself 110 electronic fertility indicator, 125 Contraceptive choice, following contraceptive failure, 83 Contraceptive failure, outcome of pregnancy and subsequent contraceptive choice, 83 Contraceptive practices, sexual habits and fertility patterns, community-based study, 445 Contraceptive regimen using GnRHA, 289 Copper release from IUDs, effect of tarnish, 385 Copper T 220, effect on endometrium, 367 Copper T 380A, clinical trial, 141 Copper T 380Ag, seven-year clinical study, 473
680
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Copper-releasing IUDs, review article, 573 Copper-T IUDs, clinical study, 481 review of literature, 341 Delaying menses, use of ethinylestradiol + desogestrel, 107 Depo-medroxyprogesterone acetate, effect on carbohydrate metabolism, 419 effect on coagulation factors, 431 effect on hormonal profile, 419 effect on lipid metabolism, 61, 431 serum level following administration, 61 Desogestrel, characteristics, 1 Diaphragm, clinical study, 21 Diaphragm tampon, Gynaeseal, 607 used with Billings Ovulation Method, 607 Discontinuation, use of biodegradable levonorgestrel implants, 409 Discontinuation rates and reasons, ethinyl estradiol + norethindrone, 489 mestranol + norethindrone, 489 Embelin (2,5-dihydroxy-3-undecyl-1,4_benzoquinone), effect on uterine peroxidase activity (rat), 549 mode of action (male rabbit), 311 Endometrial bleeding, effect of norethisterone enanthate, 73 Endometrial histology, effect of norethisterone enanthate, 73 Endometrial morphology, effect of intranasal norethisterone, 245 Endometrium, effect of IUDs, 367 Estradiol level, effect of estradiol/progesterone administration, 45 Estradiol valerate + norethisterone enanthate, clinical trial, 589 effect on lipid metabolism, 235 Estradiol/progesterone sustained release formulation, effect on ovulation, 45 Estrogenic/antiestrogenic potential of antifertility substances, effect on uterine peroxidase activity (rat), 549 Ethinylestradiol + desogestrel, ability to postpone withdrawal bleeding, 107 effect on hypothalamo-pituitary axis, 155 maintenance of remission of hirsutism, 533 Ethinyl estradiol + gestodene, effect on lipid metabolism, 235 Ethinyl estradiol + norethindrone, clinical study, 489 effect on lipid metabolism in at-risk populations, 505 rates and reasons for discontinuation, 489 treatment for hirsutism, 113 Ethinyl estradiol + norethindrone acetate, treatment for hirsutism, 113
DECEMBER 1991 VOL. 44 NO. 6
661
Failed contraception, outcome of pregnancy and subsequent contraceptive choice, 83 Family planning aid, Bioself 110 electronic fertility indicator, 125 Fern Cap, clinical trial, 11 intravaginal barrier contraceptive device, 11 Female condom, Femshie&j, 183 Female condom (Reality ), effect on lower genital tract, 21 effect on resident bacterial flora, 21 effect on vaginal mucosa and/or vulvar skin, 21 Female sterilization, acceptance and regret, 623 physicians' attitudes, recommendations and practice, Fernshield.wgl acceptability, 183 vaginal sheath, 183 Fertility indicator, Bioself 110 electronic device, 125 Fertility patterns, contraceptive practices and sexual habits, community-based study, 445 Folliculogenesis, effect of intranasal norethisterone, 245 FSH (follicle stimulating hormone) administration, FSH level, effect of estradiol/progesterone 45 Fucoidin, effect on spermatozoa, 657 effect on zona pellucida-sperm interaction, 657 Gestodene, characteristics, 1 GnRHA (gonadotrophin-releasing hormone agonist) GnRHA contraceptive regimen, cancer risk estimates, 289 Gonadotrophin-releasing hormone agonist (GnRHA), effect on bone metabolism, 289 effect on lipid metabolism, 289 effect on ovarian function, 289 use in proposed contraceptive regimen, 289 Gynaeseal, diaphragm tampon, 607 Gyne T 380, clinical study, 481 Gyne T 380 Slimline, clinical study, 481 hCG stimulation test, response of women immunized with B-hCG vaccine, 453 B-hCG vaccine, study on antibodies produced, 453 Hemostatic parameters, effect of nomegestrol acetate, 599 Hirsutism, maintenance of remission with ethinyl estradiol + desogestrel, 533 treatment with ethinyl estradiol + norethindrone, 113 treatment with ethinyl estradiol + norethindrone acetate, 113 treatment with spironolactone, 113 Hirsutism score, effect of ethinyl estradiol + desogestrel, 533
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Hormonal levels, effect of antide (monkey), 667 effect of depo-medroxyprogesterone acetate, 419 effect of ethinylestradiol + desogestrel, 155 effect of ethinyl estradiol + norethindrone, 113 effect of ethinyl estradiol + norethindrone acetate, 113 effect of intranasal norethisterone, 245 effect of 3-keto-desogestrel, 393 effect of nomegestrol acetate, 599 effect of norethisterone enanthate, 73, 419 effect of spironolactone, 113 effect of treatment with neem oil (monkey), 319 Hypospadias in infants, association to maternal oral contraceptive use, 173 Hypothalamo-pituitary axis, effect of ethinylestradiol + desogestrel, 155 Immunization with sperm antigen, effect on fertility (rat), 559 Implant contrficeptive, Capronor , 409 3-keto-desogestrel, 393 levonorgestrel, 163, 217, 409 norethindrone acetate (monkey), 327 Infant development, use of norgestrel in lactating women, 31 Infant hypospadias, association to maternal oral contraceptive use, 173 Injectable contraceptive, depo-medroxyprogesterone acetate, 61, 419, 431 estradiol valerate + norethisterone enanthate, 235, 589 estradiol/progesterone sustained release formulation, 45 norethisterone enanthate 73, 419, 639 Insertion procedure, Norplant k , 217 Intestinal complication, five years after Nova-T insertion, 517 Intranasal administration, norethisterone, 245 Intrauterine device (IUD), copper T 220, 367 Copper T 380A, 141, 385, 573 copper T 380Ag, 473, 573 copper-T devices, 341 effect of tarnish on copper release, 385 Gyne T 380, 481 Gyne T 380 Slimline, 481 levonorgestrel-releasing, 341, 367, 473, 573 Lippes C, 235 Lippes Loop D, 141 Multiload Cu 375, 141 multiload devices, 341 Nova-T, 235, 341, 517, 573 progesterone-releasing, 341 stainless steel ring, 367 TCu-200B, 573
DECEMBER 1991 VOL. 44 NO. 6
663
CONTRACEPTION
TCu-220C, 573 TCu-380, 541 Intravaginal barrier contraceptive device, Fern Cap, 11 IUD (intrauterine device) 3-Keto-desogestrel implants, clinical trial, 393 3-Keto-desogestrel level, during use of 3-keto-desogestrel implants, 393 Levonorgestrel, effect on carbohydrate metabolism, 163 metabolic effects, 223 Levonorgestrel biodegradable implant, clinical trial, 409 Levonorgestrel-releasing IUD, advantages of use, 573 disadvantages of use, 573 effect on endometrium, 367 performance, 573 review article, 573 review of literature, 341 seven-year clinical study, 473 traits comparable to copper-releasing IUDs, 573 LH (luteinizing hormone) LH level, effect of embelin (male rabbit), 311 effect of estradiol/progesterone administration, 45 LHFW (luteinizing hormone-releasing hormone) LHRH antagonist, antide, 209, 667 Lipid metabolism, effect of depo-medroxyprogesterone acetate, 431 effect of estradiol valerate + norethisterone enanthate, 235 effect of ethinyl estradiol + desogestrel, 533 effect of ethinyl estradiol + gestodene, 235 effect of ethinyl estradiol + norethindrone, 505 effect of GnFUiAs, 289 effect of 3-keto-desogestrel, 393 effect of levonorgestrel, 223 effect of Lippes C, 235 effect of new progestogens, 1 effect of norethisterone, 223 effect of Nova T, 235 Lipoprotein metabolism, effect of depo-medroxyprogesterone acetate, 61 Lippes C, effect on lipid metabolism, 235 Lippes Loop D, clinical trial, 141 Long-term intrauterine contraception, levonorgestrel and copper T 380Ag IUDs, 473 serious intestinal complication after Nova-T insertion, 517 Lower genital tract, effect of diaphragm, 21 effect of female condom, 21 Male antifertility activity, 6-chloro-6-deoxyglucose (rat, boar), 649
684
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Male sterilization, acceptance and regret, 623 physicians' attitudes, recommendations and practice, 191 Menstrual cycle, effect of intranasal norethisterone, 245 effect of norethindrone acetate (monkey), 327 Mestranol + norethindrone, clinical study, 489 rates and reasons for discontinuation, 489 Metabolic effects, use of ethinyl estradiol + norethindrone, 113 use of ethinyl estradiol + norethindrone acetate, 113 use of levonorgestrel, 223 use of nomegestrol acetate, 599 use of norethisterone, 223 use of spironolactone, 113 Metabolism, effect of new progestogens, 1 Metoclopramide-stimulated prolactin level, effect of TCu380, 541 Mifepristone (RU486), effect on prostaglandin synthesis and metabolism, 89 Multiload Cu 375, clinical trial, 141 Multiload IUDs, review of literature, 341 Natural hormones estradiol/progesterone in sustained release system, use as injectable contraceptive, 45 Neem oil, antifertility activity (rat, rabbit, monkey), 319 New progestogens, characteristics in combination oral contraceptives, 1 Nomegestrol acetate, effect on hormonal, metabolic and hemostatic parameters, 599 Norethindrone, bioavailability (monkey), 327 Norethindrone level, use of subdermal implants (monkey), 327 Norethisterone, effect on cervical mucus, 245 effect on endometrial morphology, 245 effect on folliculogenesis, 245 effect on hormonal levels, 245 effect on vaginal cytology, 245 metabolic effects, 223 Norethisterone enanthate, effect on blood coagulation factors and menstrual bleeding patterns, 639 effect on carbohydrate metabolism, 419 effect on coagulation function, 73 effect on endometrial bleeding, 73 effect on endometrial histology, 73 effect on hormonal profile, 419 effect on ovarian hormones, 73 Norgestimate, characteristics, 1 Norgestrel, clinical trial, 31 effect on breastfeeding, 31
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
NorplantR, comparison of insertion procedures, 217 effect on carbohydrate metabolism, 163 Nova-T, attributes, 341 effect on lipid metabolism, 235 epidemiologic considerations, 341 review of literature, 341 review of performance, 341, 573 serious intestinal complication five years after insertion, 517 service delivery considerations, 341 ON0 802, prostaglandin analogue, 523 Oral contraceptive, ethinylestradiol + desogestrel, 107, 155, 533 ethinylestradiol + gestodene, 235 ethinyl estradiol + norethindrone, 113, 489, 505 ethinyl estradiol + norethindrone acetate, 113 levonorgestrel, 223 mestranol + norethindrone, 489 nomegestrol acetate, 599 norethisterone, 223 norgestrel, 31 Oral contraceptive use, association to infant hypospadias, 173 Oral contraceptives, effect on vitamin status, 277 progestogen component of combination formulations, 1 Ovarian function, effect of GnRHAs, 289 Ovulation, effect of antide (monkey), 667 Ovulation method of birth control, efficacy and acceptability, 607 Performance, Nova-T, 341 PG (prostaglandin) PGF2, levels, in normal saline-induced abortions, 99 Physicians' attitudes, recommendation and practice of male and female sterilization, 191 Pituitary response, use of ethinylestradiol + desogestrel, 155 Postponement of withdrawal bleeding, use of ethinylestradiol + desogestrel, 107 Potency, various progestogens, 1 Pregnancy, effect of antide (rat), 209 effect of CDRI-85/287 (rat), 461 Pregnancy outcome, foliowing contraceptive failure, 83 Premenopausal women, effect of ethinyl estradiol + norethindrone, 505 Progesterone level, effect of antide (rat), 209 effect of embelin (male rabbit), 311 effect of estradiol/progesterone administration, 45 effect of ST-1435, 269 response in women immunized with 8-hCG vaccine, 453
DECEMBER 1991 VOL. 44 NO. 6
CONTRACEPTION
Progesterone-releasing IUD, review of literature, 341 Progestogens, in combination oral contraceptives, 1 Prolactin level, effect of TCu-380, 541 Prolonged intrauterine contraception, levonorgestrel and copper T 380Ag IUDs, 473 Prostaglandin analogue, ON0 802, 523 ndin synthesis and metabolism, effect of RU486, 89 ;:z;y;;#l effe& on lower genital tract, 21 female condom, 21 Regret, following sterilization, 623 Removals, use of 3-keto-desogestrel implants, 393 Review paper, Nova-T IUD, 341 RU486 (mifepristone) RU486 + ON0 802, acceptability as an abortion method, 523 side effects during treatment, 523 use for early termination of pregnancy, 523 Saline-induced abortions, PGF2, levels, 99 Sexual habits, contraceptive practices and fertility patterns, community-based study, 445 Side effects, use of biodegradable levonorgestrel implants, 409 use of estradiol valerate + norethisterone enanthate, 589 use of ethinyl estradiol + norethindrone, 489 use of GnRHAs, 289 use of IUDs, 141 use of mestrano + norethindrone, 489 use of Norplant h , 217 Smoking women, effect of ethinyl estradiol + norethindrone, 505 Sperm antigen, potential for use as contraceptive vaccine (rat), 559 Sperm antigen immunization, antifertility effects (rat), 559 Spermatozoa, effect of 6-chloro-6-deoxyglucose (rat, boar), 649 effect of fucoidin, 657 Spironolactone, treatment for hirsutism, 113 ST-1435 (16-methy1ene-17-acetoxy-19-nor-4-pregnene-3,20dione), transdermal absorption, 269 ST-1435 level, following transdermal application of ST-1435, 269 Stainless steel ring, effect on endometrium, 367 Sterilization, acceptance and regret, 623 factors affecting choice, 623 physicians' attitudes, recommendations and practice, 191 Steroidal effects, various progestogens, 1 Tarnish, effect on copper release from IUDs, 385 TCu IUDs, review of performance, 573 TCu-380, effect on prolactin levels, 541 Termination events, comparative clinical trials of IUDs, 141
DECEMBER 1991 VOL. 44 NO. 6
667
CONTRACEPTION
Termination of pregnancy, use of RU486 and ON0 802 in combination, 523 Testosterone level, effect of embelin (rabbit), 311 effect of ethinyl estradiol + desogestrel, 533 Transdermal absorption, ST-1435, 269 Triphasic ethinylestradiol + gestodene, effect on lipid metabolism, 235 Tubal ligation, physicians' attitudes, recommendations and practice, 191 Uterine peroxidase activity, effect of antifertility substances (rat), 549 Uterine weight, effect of antifertility substances (rat), 549 Uterus, effect of CDRI-851287 (rat, rabbit), 461 Vaccine contraceptive, B-hCG vaccine, 453 Vaginal bacterial flora, effect of diaphragm, 21 effect of female condom, 21 Vaginal cytology, effect of intranasal norethisterone, 245 Vasectomy, physicians' attitudes, recommendations and practice, 191 Vitamin status, effect of oral contraceptives, 277 Vitamin supplementation, effect in oral contraceptive users, 277 Zona pellucida-sperm interaction, effect of fucoidin, 657
DECEMBER 1991 VOL. 44 NO. 6